Insights from 2023 ASH Annual Meeting

 

Insights from 2023 ASH Annual Meeting
M

FLT3-ITD Mutated AML: Quizartinib, Venetoclax, & Decitabine Triple Combination

By Insights from 2023 ASH Annual Meeting FEATURING Musa Yilmaz
By Insights from 2023 ASH Annual Meeting FEATURING Musa Yilmaz
116 views
December 15, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

05:11
Pharmacosmos Hematology

A discussion on the safety of an IV iron replacement therapy

Feat. H. Bahrain
Leukemia
05:08
Insights from 2023 ASH Annual Meeting

Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOI…

Feat. P. Ghia
06:13
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartin…

Feat. E. Oliva
20:28
Insights from 2023 ASH Annual Meeting

Clinically-Relevant Updates in ALL in Adults

Feat. R. Cassaday
08:45
Insights from 2023 ASH Annual Meeting

The Best of CLL: Highlights & Key Takeaways

Feat. V. Yazbeck
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
21:20
Insights from 2023 ASH Annual Meeting

The Future Paradigm of HMA + Ven or Targeted Agents in AML: Sequenci…

Feat. J. Watts
06:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "NPM1-Mutated Myeloid Neoplasms - Outcomes W…

Feat. G. Montalban Bravo
09:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatin…

Feat. J. Cortés
11:36
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Maintenance Rux Is Associated With Low Rate…

Feat. Z. DeFilipp
09:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax + Pegcrisantaspase in R/R AML - …

Feat. Y. Liu
13:15
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Bezuclastinib (CGT9486), a Novel KIT D816V …

Feat. P. Vachhani
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
06:49
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Ad…

Feat. M. Luskin
07:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Inotuzumab Ozogamicin for R…

Feat. M. Luskin
04:45
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The Impact of Inotuzumab Ozogamicin Treatme…

Feat. I. Aldoss
05:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Revumenib Monotherapy in Pts With R/R KMT2A…

Feat. I. Aldoss
09:19
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Ob…

Feat. M. Fürstenau
13:31
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "COVALENT-101 Study - Covalent Menin Inhibit…

Feat. J. Lancet
01:44
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Optimizing Outcomes With Myeloablative Cond…

Feat. C. Oliai
07:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …

Feat. E. Atallah
10:08
Insights from 2023 ASH Annual Meeting

Comparison of Venetoclax Based Treatments for Patients With R/R CLL

Feat. B. Heyman
18:27
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: QuANTUM-First - Safety by Treatment Phase and …

Feat. H. Erba
18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
04:21
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Improving Long-Term Outcomes With Intensive…

Feat. C. Röllig
03:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatin…

Feat. E. Jabbour
11:00
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Oral Decitabine/Cedazuridine (ASTX727) &…

Feat. H. Atluri
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
08:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Tre…

Feat. D. Yeung
14:40
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "AYAs With ALL - Treatment Approaches and On…

Feat. E. Curran
14:10
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Relapse Incidence Post Unrelated alloSCT Wi…

Feat. A. Nagler
06:56
Insights from 2023 ASH Annual Meeting

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…

Feat. M. Shadman
07:04
Insights from 2023 ASH Annual Meeting

Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patient…

Feat. M. Shadman
08:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosiden…

Feat. A. Ambinder
08:26
Insights from 2023 ASH Annual Meeting

CLL/SLL Treatment With Post-cBTKi Pirtobrutinib: 30 Months Follow-Up…

Feat. J. Woyach
06:17
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Revumenib Maintenance Therapy Following Rev…

Feat. A. Zucenka
05:12
Insights from 2023 ASH Annual Meeting

R/R CLL Treated With Fixed-Duration Pirtobrutinib Combined With Vene…

Feat. N. Shah
07:06
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effectiveness of Venetoclax-Based Therapy A…

Feat. N. Ghosh
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effect of Ibrutinib Flexible Dosing Strateg…

Feat. N. Ghosh
07:22
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Hypertension in Pts With CLL and Other Heme…

Feat. A. Ferrajoli
09:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Long-Term Analysis of Lenalidomide & …

Feat. C. Chen
07:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to…

Feat. K. Rogers
07:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Understanding Differential Technologies for…

Feat. J. Cloos
10:32
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: Quizartinib, Venetoclax, & Decitabine Trip…

Feat. M. Yilmaz
07:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Re…

Feat. M. Amaya
06:57
Insights from 2023 ASH Annual Meeting

TN-CLL/SLL: Combination Treatment With Sonrotoclax (BGB-11417), a 2n…

Feat. M. Ann Anderson
05:28
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Performance of the Molecular International …

Feat. K. Chien
10:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not …

Feat. D. Tremblay